logo-loader
RNS
Amryt Pharma PLC

Euronext Growth Dublin Suspension Notice

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .v{size:595.3pt 841.9pt;margin:106.35pt 72.0pt 72.0pt 72.0pt;}div.v{}table.az{width:474.9pt;border-collapse:collapse}tr.as{height:10.65pt}td.av{width:177.2pt;padding:0cm 0cm 0cm 0cm; height:10.65pt}p.ba{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 107%}span.ax{font-size:9.0pt;line-height:107%;font-family:"Arial","sans-serif"}td.at{width:297.7pt;padding:0cm 0cm 0cm 0cm; height:10.65pt}p.bb{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";line-height:107%}tr.ap{height:12.0pt} td.ar{width:177.2pt;padding:0cm 0cm 0cm 0cm; height:12.0pt}td.aq{width:297.7pt;padding:0cm 0cm 0cm 0cm; height:12.0pt}p.bc{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;line-height:107%}span.bd{color:gray;font-size:9.0pt;line-height:107%;font-family:"Arial","sans-serif"; color:windowtext}span.be{color:gray;font-size:9.0pt;line-height: 107%;font-family:"Arial","sans-serif";color:windowtext}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}span.ak{font-size:9.0pt;font-family:"Arial","sans-serif"; color:black}p.bf{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;line-height:15.0pt}span.aj{font-size:9.0pt;font-family:"Arial","sans-serif"}table.bg{margin-left:-5.4pt;border-collapse:collapse;border:none} td.ah{width:129.3pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.ag{width:286.85pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.af{width:129.3pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.ae{width:286.85pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.ac{font-size:10.0pt;font-family:"Calibri","sans-serif"}p.bh{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";line-height: 15.0pt; text-align: center}span.aa{font-family:"Calibri","sans-serif"; color:black}p.bi{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:0cm;margin-bottom:.15pt; margin-left:-.25pt;text-align:justify;text-indent:-.5pt;line-height:130%}span.z{font-size:8.0pt;line-height:130%;font-family:"Calibri","sans-serif"; color:black}span.x{font-size:8.0pt;line-height:130%;font-family:"Calibri","sans-serif"} span.w{color:black} /**/
RNS Number : 6686Z
Euronext Dublin
21 May 2019
 

CORPORATE EVENT NOTICE:

Suspension Notice


Amryt Pharma Plc



LOCATION:

Dublin



DATE:

21st May 2019

MARKET:

Euronext Growth

 

 

Trading of the under-mentioned securities of Amryt Pharma Plc have been temporarily suspended, as detailed below.

 

Date and time of the communication

2019-05-21T07:30:00Z

Action type

Suspension of trading

Reasons for the action

Announcement has been released in respect of a Reverse takeover in accordance with Euronext Growth rule 14

Effective from

2019-05-21T07:30:00Z

Effective to


Ongoing

True

Trading venue(s)

XESM

Issuer name

Amryt Pharma Plc

Issuer Legal Entity Identifier (LEI)

213800BOS8WAJO2BEQ38

Instrument identifier (ISIN)

GB00BDD1LS57

Instrument full name

Ordinary Shares

Sufficiently related derivatives


Other related instruments


Comments


 

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.

 

The present notice and the contents thereof are only provided for information purposes in order to facilitate the fair, orderly and efficient functioning of the market and is not a recommendation to engage in investment activities. The contents of this notice are provided "as is" based on information provided to the market operator without representation or warranty of any kind. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this notice shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator.

 

The Euronext Markets comprise the markets operated by Euronext Amsterdam, Euronext Brussels, Euronext Dublin, Euronext Lisbon, Euronext Paris and Euronext UK Markets, referred to respectively as the Amsterdam, Brussels, Dublin, Lisbon, Paris and London markets, as relevant.

 

Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at https://www.euronext.com/terms-use.

 

© 2019 Euronext N.V.  - All rights reserved

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEQFLBLKEFFBBQ

Quick facts: Amryt Pharma PLC

Price: £1.29

Market: AIM
Market Cap: £64.99 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

RNS

Circular to Shareholders

3 days, 23 hours ago

Update on Acquisition of Aegerion

5 days, 15 hours ago

Schedule One

1 week, 5 days ago

Schedule One - Amryt Pharma plc

1 week, 5 days ago

Holdings in Company

2 weeks ago

Holding(s) in Company

2 weeks, 4 days ago